Last reviewed · How we verify
Amlodipine, Losartan
At a glance
| Generic name | Amlodipine, Losartan |
|---|---|
| Also known as | other antihypertensive drugs (if required) |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Hypertension in Young Adults Trial (PHASE2)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) (PHASE2)
- A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) (PHASE3)
- Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) (PHASE2)
- Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design (NA)
- Arterial Stiffness and Blood Pressure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine, Losartan CI brief — competitive landscape report
- Amlodipine, Losartan updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI